Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Izutsu, Koji [1 ]
Goto, Hideki [2 ]
Kizaki, Masahiro [3 ]
Yamaguchi, Masaki [4 ]
Fukuhara, Noriko [5 ]
Kato, Koji [6 ]
Saito, Toko [7 ]
Terui, Yasuhito [8 ]
Okubo, Sumiko [9 ]
Soshin, Tomomi [9 ]
Mukherjee, Nabanita [10 ]
Honda, Hideyuki [9 ]
Badawi, Mohamed [10 ]
Ross, Jeremy [10 ]
Ishizawa, Kenichi [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hokkaido Univ Hosp, Hokkaido, Japan
[3] Saitama Med Ctr, Saitama, Japan
[4] Ishikawa Prefecture Cent Hosp, Kanazawa, Ishikawa, Japan
[5] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[6] Kyushu Univ Hosp, Fukuoka, Japan
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Saitama Med Univ Hosp, Saitama, Japan
[9] Abbvie GK, Tokyo, Japan
[10] AbbVie Inc, N Chicago, IL USA
[11] Yamagata Univ Hosp, Yamagata, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO50-5
引用
收藏
页码：S1428 / S1428
页数：1
相关论文
共 50 条
  • [41] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [42] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [43] Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
    Zhiyuan Zhou
    Lei Zhang
    Xinhua Wang
    Xin Li
    Ling Li
    Xiaorui Fu
    Xudong Zhang
    Zhaoming Li
    Zhenchang Sun
    Mingzhi Zhang
    Annals of Hematology, 2021, 100 : 1509 - 1516
  • [44] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
    Dreyling, Martin
    Jurczak, Wojciech
    Jerkeman, Mats
    Silva, Rodrigo Santucci
    Rusconi, Chiara
    Trneny, Marek
    Offner, Fritz
    Caballero, Dolores
    Joao, Cristina
    Witzens-Harig, Mathias
    Hess, Georg
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bothos, John
    Goldberg, Jenna D.
    Enny, Christopher
    Traina, Shana
    Balasubramanian, Sriram
    Bandyopadhyay, Nibedita
    Sun, Steven
    Vermeulen, Jessica
    Rizo, Aleksandra
    Rule, Simon
    LANCET, 2016, 387 (10020): : 770 - 778
  • [45] Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience
    Grilo, I. T.
    Couto, M. E.
    Freitas, J. F.
    Pereira, D. P.
    Moreira, C.
    Chacim, S.
    Domingues, N.
    Santo, A. E.
    Martins, A.
    Viterbo, L.
    Oliveira, I.
    Moreira, I.
    Mariz, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)
    Zinzani, Pier Luigi
    Delwail, Vincent
    Paneesha, Shankara
    Rule, Simon
    Garcia-Sancho, Alejandro Martin
    Marin-Niebla, Ana
    Salles, Gilles
    Sancho, Juan-Manuel
    Vergote, Vibeke
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Mehta, Amitkumar
    BLOOD, 2020, 136
  • [47] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [48] SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Peng, S.
    Sorensen, S.
    Pan, F.
    Dorman, E.
    Sun, S.
    Van Sanden, S.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A620 - A620
  • [49] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [50] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Munir, T.
    Rawstron, A.
    Brock, K.
    Vicente, S. Munoz
    Yates, F.
    Bishop, R.
    Macdonald, D.
    Fegan, C.
    McCaig, A.
    Schuh, A.
    Pettitt, A.
    Gribben, J. G.
    Patten, P. E.
    Devereux, S.
    Bloor, A.
    Fox, C. P.
    Forconi, F.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 25 - 25
12345